CA2626612A1 - Pharmaceutical compositions of muscarinic receptor antagonists - Google Patents
Pharmaceutical compositions of muscarinic receptor antagonists Download PDFInfo
- Publication number
- CA2626612A1 CA2626612A1 CA002626612A CA2626612A CA2626612A1 CA 2626612 A1 CA2626612 A1 CA 2626612A1 CA 002626612 A CA002626612 A CA 002626612A CA 2626612 A CA2626612 A CA 2626612A CA 2626612 A1 CA2626612 A1 CA 2626612A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- hydroxy
- azabicyclo
- methyl
- hexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000003246 corticosteroid Substances 0.000 claims abstract description 24
- 229960001334 corticosteroids Drugs 0.000 claims abstract description 23
- 239000000556 agonist Substances 0.000 claims abstract description 21
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 19
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 10
- 230000001363 autoimmune Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 737
- 150000003839 salts Chemical class 0.000 claims description 51
- -1 cyano, hydroxy Chemical group 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 40
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 30
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 239000001301 oxygen Substances 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 19
- 239000005864 Sulphur Chemical group 0.000 claims description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 150000001204 N-oxides Chemical class 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 229940043355 kinase inhibitor Drugs 0.000 claims description 12
- 239000002207 metabolite Substances 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 229910052757 nitrogen Chemical group 0.000 claims description 12
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 11
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 11
- 229940095064 tartrate Drugs 0.000 claims description 11
- 239000000812 cholinergic antagonist Substances 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 239000000043 antiallergic agent Substances 0.000 claims description 8
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 8
- 229940052760 dopamine agonists Drugs 0.000 claims description 8
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 6
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 4
- KNSLGPATJQAECH-UHFFFAOYSA-N 2-phenylacetamide;hydrochloride Chemical compound Cl.NC(=O)CC1=CC=CC=C1 KNSLGPATJQAECH-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 101100439664 Arabidopsis thaliana CHR8 gene Chemical group 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- GXLCAQVYIJMWCZ-UHFFFAOYSA-N (3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate Chemical compound C12CN(CC=3C=CC=CC=3)CC2C1COC(=O)C(C=1SC=CC=1)(O)C1CCCC1 GXLCAQVYIJMWCZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- HUPVBFQYJHFONM-UHFFFAOYSA-N 2-(4-fluorophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(F)C=C1 HUPVBFQYJHFONM-UHFFFAOYSA-N 0.000 claims description 3
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 3
- MYLUSPDQXBKXTC-UHFFFAOYSA-N n-phenylacetamide;hydrochloride Chemical compound Cl.CC(=O)NC1=CC=CC=C1 MYLUSPDQXBKXTC-UHFFFAOYSA-N 0.000 claims description 3
- 239000013312 porous aromatic framework Substances 0.000 claims description 3
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 17
- 239000003085 diluting agent Substances 0.000 abstract description 16
- 239000003937 drug carrier Substances 0.000 abstract description 15
- 208000035475 disorder Diseases 0.000 abstract description 9
- 208000026935 allergic disease Diseases 0.000 abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 3
- 239000003149 muscarinic antagonist Substances 0.000 description 33
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 16
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 14
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 14
- FIMXSEMBHGTNKT-RZVDLVGDSA-N scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 description 14
- 229960004373 acetylcholine Drugs 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 13
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 12
- 108010058846 Ovalbumin Proteins 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 229940092253 ovalbumin Drugs 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 9
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 9
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 9
- 229960004484 carbachol Drugs 0.000 description 9
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 8
- 229960002586 roflumilast Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 7
- 229950005741 rolipram Drugs 0.000 description 7
- 239000011975 tartaric acid Substances 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 6
- 239000001530 fumaric acid Substances 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000011976 maleic acid Substances 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 235000002906 tartaric acid Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 229960002714 fluticasone Drugs 0.000 description 5
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- ODELFXJUOVNEFZ-UHFFFAOYSA-N 2,2-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C(O)=O)(C)C1=CC=CC=C1 ODELFXJUOVNEFZ-UHFFFAOYSA-N 0.000 description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 229960004436 budesonide Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960003728 ciclesonide Drugs 0.000 description 4
- 229960001867 guaiacol Drugs 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- MAGCRYYXZYUDSY-UHFFFAOYSA-N 2-fluoro-2,2-diphenylacetic acid Chemical compound C=1C=CC=CC=1C(F)(C(=O)O)C1=CC=CC=C1 MAGCRYYXZYUDSY-UHFFFAOYSA-N 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000036428 airway hyperreactivity Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229960001271 desloratadine Drugs 0.000 description 3
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 3
- 229950000579 enprofylline Drugs 0.000 description 3
- 229960003449 epinastine Drugs 0.000 description 3
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000676 flunisolide Drugs 0.000 description 3
- 229960001361 ipratropium bromide Drugs 0.000 description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229960001664 mometasone Drugs 0.000 description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960005294 triamcinolone Drugs 0.000 description 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 3
- DYRRBMLFLLRLKB-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 DYRRBMLFLLRLKB-UHFFFAOYSA-N 0.000 description 2
- OBWCIXSXYKHZQK-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methoxypyridin-3-yl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound C1=NC(OC)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 OBWCIXSXYKHZQK-UHFFFAOYSA-N 0.000 description 2
- ZMXHONJJTQSZKY-UHFFFAOYSA-N 2,2-bis(3,4-difluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C(F)=CC=1C(O)(C(=O)O)C1=CC=C(F)C(F)=C1 ZMXHONJJTQSZKY-UHFFFAOYSA-N 0.000 description 2
- RCORMCWYMRPHPO-UHFFFAOYSA-N 2,2-bis(3-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=CC(F)=CC=1C(O)(C(=O)O)C1=CC=CC(F)=C1 RCORMCWYMRPHPO-UHFFFAOYSA-N 0.000 description 2
- BDRDNPBTWIGWPI-UHFFFAOYSA-N 2-(cyclobutylamino)-6-(2-methylphenyl)-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCC1 BDRDNPBTWIGWPI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IGMXFRVKNJSCNP-UHFFFAOYSA-N 2-[(1-benzoylpiperidin-4-yl)amino]-6-(2-methylphenyl)-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCN(C(=O)C=2C=CC=CC=2)CC1 IGMXFRVKNJSCNP-UHFFFAOYSA-N 0.000 description 2
- HRHPMXNLUBSVQE-UHFFFAOYSA-N 2-[(1-benzylpiperidin-4-yl)amino]-6-(2-methylphenyl)-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCN(CC=2C=CC=CC=2)CC1 HRHPMXNLUBSVQE-UHFFFAOYSA-N 0.000 description 2
- NVMXARWNJKMDRI-UHFFFAOYSA-N 2-[(1-ethylsulfonylpiperidin-4-yl)amino]-6-(2-methylphenyl)-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(S(=O)(=O)CC)CCC1NC1=NC=C(C=C(C=2C(=CC=CC=2)C)C(=O)N2C3CCOCC3)C2=N1 NVMXARWNJKMDRI-UHFFFAOYSA-N 0.000 description 2
- AWZQYZNWDPTGOT-UHFFFAOYSA-N 2-cyclohexyl-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)C1CCCCC1 AWZQYZNWDPTGOT-UHFFFAOYSA-N 0.000 description 2
- YWWQABBXZSDJEK-UHFFFAOYSA-N 3-(3-cycloheptyloxy-4-cyclopentyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCC1OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 YWWQABBXZSDJEK-UHFFFAOYSA-N 0.000 description 2
- JNJZDZZUUFIKSD-UHFFFAOYSA-N 3-[3-(cyclopropylmethoxy)-4-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CC1 JNJZDZZUUFIKSD-UHFFFAOYSA-N 0.000 description 2
- FDPZQXNVRVWNGO-UHFFFAOYSA-N 4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-n-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCN(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)CC1 FDPZQXNVRVWNGO-UHFFFAOYSA-N 0.000 description 2
- KTNSFXYCJPHYLC-UHFFFAOYSA-N 4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-n-propylpiperazine-1-carboxamide Chemical compound C1CN(C(=O)NCCC)CCN1NC1=NC=C(C=C(C=2C(=CC=CC=2)C)C(=O)N2C3CCOCC3)C2=N1 KTNSFXYCJPHYLC-UHFFFAOYSA-N 0.000 description 2
- SFSGILHAYAHHBB-UHFFFAOYSA-N 6-(2-methylphenyl)-2-[(1-methylpiperidin-4-yl)amino]-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C)CCC1NC1=NC=C(C=C(C=2C(=CC=CC=2)C)C(=O)N2C3CCOCC3)C2=N1 SFSGILHAYAHHBB-UHFFFAOYSA-N 0.000 description 2
- NLIGKYMEJCIDJJ-UHFFFAOYSA-N 6-(2-methylphenyl)-2-[(1-methylsulfonylpiperidin-4-yl)amino]-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCN(S(C)(=O)=O)CC1 NLIGKYMEJCIDJJ-UHFFFAOYSA-N 0.000 description 2
- UMDOYKWTNIITDJ-UHFFFAOYSA-N 6-(2-methylphenyl)-8-(oxan-4-yl)-2-[(4-propan-2-ylsulfonylpiperazin-1-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(S(=O)(=O)C(C)C)CCN1NC1=NC=C(C=C(C=2C(=CC=CC=2)C)C(=O)N2C3CCOCC3)C2=N1 UMDOYKWTNIITDJ-UHFFFAOYSA-N 0.000 description 2
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 2
- FFHCKAMBYOUOQN-UHFFFAOYSA-N N-(4-fluorophenyl)-4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]piperazine-1-carboxamide Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NN1CCN(C(=O)NC=2C=CC(F)=CC=2)CC1 FFHCKAMBYOUOQN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- MVCOAUNKQVWQHZ-UHFFFAOYSA-N doramapimod Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 MVCOAUNKQVWQHZ-UHFFFAOYSA-N 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- YXOKBHUPEBNZOG-UHFFFAOYSA-N hydron;4-hydroxy-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]ethylamino]ethyl]-3h-1,3-benzothiazol-2-one;chloride Chemical compound Cl.C1=2SC(=O)NC=2C(O)=CC=C1CCNCCS(=O)(=O)CCCOCCC1=CC=CC=C1 YXOKBHUPEBNZOG-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical class O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 2
- 229960001120 levocabastine Drugs 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960001144 mizolastine Drugs 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- HQEGVAQPKGBNKQ-UHFFFAOYSA-N n-(4-fluorophenyl)-4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]piperidine-1-carbothioamide Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCN(C(=S)NC=2C=CC(F)=CC=2)CC1 HQEGVAQPKGBNKQ-UHFFFAOYSA-N 0.000 description 2
- GORMZSUEBYAXDY-UHFFFAOYSA-N n-(4-fluorophenyl)-4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]piperidine-1-carboxamide Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCN(C(=O)NC=2C=CC(F)=CC=2)CC1 GORMZSUEBYAXDY-UHFFFAOYSA-N 0.000 description 2
- JZSAXZCTBHXRAV-UHFFFAOYSA-N n-cyclohexyl-4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]piperazine-1-carboxamide Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NN1CCN(C(=O)NC2CCCCC2)CC1 JZSAXZCTBHXRAV-UHFFFAOYSA-N 0.000 description 2
- CVSWUEXZWSBDMC-UHFFFAOYSA-N non-2-ene Chemical compound CCCCCC[CH]C=C CVSWUEXZWSBDMC-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229960005434 oxybutynin Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 229950008418 talipexole Drugs 0.000 description 2
- VTRQFQXIVJEXDT-UHFFFAOYSA-N tert-butyl 4-[[6-(2-chlorophenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=NC=C(C=C(C=2C(=CC=CC=2)Cl)C(=O)N2C3CCOCC3)C2=N1 VTRQFQXIVJEXDT-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229960000257 tiotropium bromide Drugs 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- 229960004045 tolterodine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- DPVJZWJFXGRGJO-SFHVURJKSA-N (5r)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2C[C@@]3(COCC3)ON=2)C=C1OC1CCCC1 DPVJZWJFXGRGJO-SFHVURJKSA-N 0.000 description 1
- DPVJZWJFXGRGJO-GOSISDBHSA-N (5s)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2C[C@]3(COCC3)ON=2)C=C1OC1CCCC1 DPVJZWJFXGRGJO-GOSISDBHSA-N 0.000 description 1
- KQZSMOGWYFPKCH-UJPCIWJBSA-N (8s,9s,10r,11s,13s,14s,17r)-17-acetyl-11,17-dihydroxy-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O KQZSMOGWYFPKCH-UJPCIWJBSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- DOSVYTLBYMQKTC-UHFFFAOYSA-N 1,2,3,5-tetrahydro-2-benzazepin-4-one Chemical class C1C(=O)CNCC2=CC=CC=C21 DOSVYTLBYMQKTC-UHFFFAOYSA-N 0.000 description 1
- XVOWNEOOAGXOCX-UHFFFAOYSA-N 1,2-diazaspiro[4.5]dec-2-ene Chemical compound C1C=NNC11CCCCC1 XVOWNEOOAGXOCX-UHFFFAOYSA-N 0.000 description 1
- HJCRSXYVPNDWDX-RBFZIWAESA-N 1-[(2r)-2-[[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl]pyrrolidin-1-yl]propan-1-one Chemical compound CCC(=O)N1CCC[C@@H]1COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F HJCRSXYVPNDWDX-RBFZIWAESA-N 0.000 description 1
- VTIRXKHOOLRNDQ-OOJLDXBWSA-N 1-[(2s)-2-[[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl]pyrrolidin-1-yl]ethanone Chemical compound CC(=O)N1CCC[C@H]1COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F VTIRXKHOOLRNDQ-OOJLDXBWSA-N 0.000 description 1
- DIQKIPUYXSNLNR-PVCZSOGJSA-N 1-[(3s)-3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CC[C@@H]1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F DIQKIPUYXSNLNR-PVCZSOGJSA-N 0.000 description 1
- QXCFQUOIWNHMJB-UHFFFAOYSA-N 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-en-7-yl]ethanone Chemical compound COC1=CC=C(C=2CC3(CN(CC3)C(C)=O)ON=2)C=C1OC1CCCC1 QXCFQUOIWNHMJB-UHFFFAOYSA-N 0.000 description 1
- KQNRZHISYIUFFD-UHFFFAOYSA-N 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]ethanone Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CC3)C(C)=O)C=C1OC1CCCC1 KQNRZHISYIUFFD-UHFFFAOYSA-N 0.000 description 1
- JQTSMCFPUBMDPZ-UHFFFAOYSA-N 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-en-9-yl]ethanone Chemical compound COC1=CC=C(C=2CC3(ON=2)CN(CCC3)C(C)=O)C=C1OC1CCCC1 JQTSMCFPUBMDPZ-UHFFFAOYSA-N 0.000 description 1
- MTZJLAGINISZEJ-UHFFFAOYSA-N 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl]-1-(2-methoxyphenyl)urea Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(CC3)N(C(N)=O)C=2C(=CC=CC=2)OC)C=C1OC1CCCC1 MTZJLAGINISZEJ-UHFFFAOYSA-N 0.000 description 1
- KMFUVVRLBOYMAY-UHFFFAOYSA-N 1-[3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F KMFUVVRLBOYMAY-UHFFFAOYSA-N 0.000 description 1
- NXTVNOKGNYDNBY-UHFFFAOYSA-N 1-[3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CCCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F NXTVNOKGNYDNBY-UHFFFAOYSA-N 0.000 description 1
- JAJTVVDBPOVKQM-UHFFFAOYSA-N 1-[4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F JAJTVVDBPOVKQM-UHFFFAOYSA-N 0.000 description 1
- LECHGRBFRSCYPJ-UHFFFAOYSA-N 1-[4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]propan-1-one Chemical compound C1CN(C(=O)CC)CCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F LECHGRBFRSCYPJ-UHFFFAOYSA-N 0.000 description 1
- UQDWAVPZBOQOCI-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-[2-(1-oxo-1,4-thiazinan-4-yl)ethoxy]naphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCN3CCS(=O)CC3)=CC=2)=CC(C(C)(C)C)=N1 UQDWAVPZBOQOCI-UHFFFAOYSA-N 0.000 description 1
- APRDOMOEBUWBDX-UHFFFAOYSA-N 1-[5-tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-yl]-3-[4-(2-pyridin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound C1=NC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(OCCC=3C=CN=CC=3)=CC=2)=CC(C(C)(C)C)=N1 APRDOMOEBUWBDX-UHFFFAOYSA-N 0.000 description 1
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 1
- XZVKOMOTDZLLDN-UHFFFAOYSA-N 1-methyl-10-[2-(4-methylpiperazin-1-yl)acetyl]-5h-thieno[3,4-b][1,5]benzodiazepin-4-one;hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 XZVKOMOTDZLLDN-UHFFFAOYSA-N 0.000 description 1
- POXWDTQUDZUOGP-UHFFFAOYSA-N 1h-1,4-diazepine Chemical compound N1C=CC=NC=C1 POXWDTQUDZUOGP-UHFFFAOYSA-N 0.000 description 1
- YKZXWNCXGVYCKF-UHFFFAOYSA-N 2,2-bis(4-fluorophenyl)-2-hydroxyacetic acid Chemical compound C=1C=C(F)C=CC=1C(O)(C(=O)O)C1=CC=C(F)C=C1 YKZXWNCXGVYCKF-UHFFFAOYSA-N 0.000 description 1
- SDVFSDZZYXTWCL-UHFFFAOYSA-N 2,2-bis(4-fluorophenyl)-2-hydroxyacetic acid;bromoethane Chemical compound CCBr.C=1C=C(F)C=CC=1C(O)(C(=O)O)C1=CC=C(F)C=C1 SDVFSDZZYXTWCL-UHFFFAOYSA-N 0.000 description 1
- YPRHEPKTGFUHCK-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-yloxy)-4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(O)=CC=C1C(C1)=NOC21CCOC2 YPRHEPKTGFUHCK-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- BHTUDTDVIWMCQM-UHFFFAOYSA-N 2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol Chemical compound C1=C(OC(F)F)C(O)=CC(C=2CC3(COCC3)ON=2)=C1 BHTUDTDVIWMCQM-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- PHXFOTHELKXSCA-UHFFFAOYSA-N 2-[(1-acetylpiperidin-4-yl)amino]-6-(2-methylphenyl)-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C(=O)C)CCC1NC1=NC=C(C=C(C=2C(=CC=CC=2)C)C(=O)N2C3CCOCC3)C2=N1 PHXFOTHELKXSCA-UHFFFAOYSA-N 0.000 description 1
- ORABMQSVAJXFTQ-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]-n-methylacetamide Chemical compound C1=C(OC(F)F)C(OCC(=O)NC)=CC(C=2CC3(COCC3)ON=2)=C1 ORABMQSVAJXFTQ-UHFFFAOYSA-N 0.000 description 1
- WSXGQCQWPNRNBR-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetamide Chemical compound C1=C(OC(F)F)C(OCC(=O)N)=CC(C=2CC3(COCC3)ON=2)=C1 WSXGQCQWPNRNBR-UHFFFAOYSA-N 0.000 description 1
- MOWKSKDNBFDKRV-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetonitrile Chemical compound C1=C(OCC#N)C(OC(F)F)=CC=C1C(C1)=NOC11COCC1 MOWKSKDNBFDKRV-UHFFFAOYSA-N 0.000 description 1
- YMURQVVCUSLYKS-UHFFFAOYSA-N 2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]ethanol Chemical compound C1=C(OC(F)F)C(OCCO)=CC(C=2CC3(COCC3)ON=2)=C1 YMURQVVCUSLYKS-UHFFFAOYSA-N 0.000 description 1
- FGMJOLZIJYUYRN-UHFFFAOYSA-N 2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetamide Chemical compound C1=C(OCC(N)=O)C(OC)=CC=C1C(C1)=NOC11COCC1 FGMJOLZIJYUYRN-UHFFFAOYSA-N 0.000 description 1
- PJTOVCQEWMEDFI-UHFFFAOYSA-N 2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetonitrile Chemical compound C1=C(OCC#N)C(OC)=CC=C1C(C1)=NOC11COCC1 PJTOVCQEWMEDFI-UHFFFAOYSA-N 0.000 description 1
- GMNDCMQPBWZHLK-UHFFFAOYSA-N 2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]cyclopentan-1-ol Chemical compound COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1O GMNDCMQPBWZHLK-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- JSUQXHOMGSWZBI-UHFFFAOYSA-N 2-cyclopentyl-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(C(=O)N)C1CCCC1 JSUQXHOMGSWZBI-UHFFFAOYSA-N 0.000 description 1
- NNCQRRYTAYEFDO-UHFFFAOYSA-N 2-cyclopentyloxy-4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol Chemical compound OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 NNCQRRYTAYEFDO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- JZDSOQSUCWVBMV-UHFFFAOYSA-N 2-ethylisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CC)C(=O)C2=C1 JZDSOQSUCWVBMV-UHFFFAOYSA-N 0.000 description 1
- BWYJJZBRYSADRP-UHFFFAOYSA-N 2-methoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC=C21 BWYJJZBRYSADRP-UHFFFAOYSA-N 0.000 description 1
- ZMPRRFPMMJQXPP-UHFFFAOYSA-N 2-sulfobenzoic acid Chemical class OC(=O)C1=CC=CC=C1S(O)(=O)=O ZMPRRFPMMJQXPP-UHFFFAOYSA-N 0.000 description 1
- FSGMUUWIXPCDDX-UHFFFAOYSA-N 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1OCCC21ON=C(C=1C=C3OCCOC3=CC=1)C2 FSGMUUWIXPCDDX-UHFFFAOYSA-N 0.000 description 1
- UPTMVIKIZMEHFW-UHFFFAOYSA-N 3-(3,4-dicyclopentyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCC1OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 UPTMVIKIZMEHFW-UHFFFAOYSA-N 0.000 description 1
- NAGHGSBKEYNIAA-UHFFFAOYSA-N 3-(3-butoxy-4-cyclohexyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCCC1 NAGHGSBKEYNIAA-UHFFFAOYSA-N 0.000 description 1
- GKFDYDIBPWPJDH-UHFFFAOYSA-N 3-(3-butoxy-4-cyclopentyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 GKFDYDIBPWPJDH-UHFFFAOYSA-N 0.000 description 1
- VSHYHRWYSGFZIM-UHFFFAOYSA-N 3-(3-butoxy-4-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC)C(OCCCC)=CC(C=2CC3(COCC3)ON=2)=C1 VSHYHRWYSGFZIM-UHFFFAOYSA-N 0.000 description 1
- UEIBXNATDIOJQT-UHFFFAOYSA-N 3-(3-butoxy-4-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCCCC)=CC(C=2CC3(COCC3)ON=2)=C1 UEIBXNATDIOJQT-UHFFFAOYSA-N 0.000 description 1
- WRICPQCEBQENKD-UHFFFAOYSA-N 3-(3-butoxy-4-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCCC)C(OCCCC)=CC(C=2CC3(COCC3)ON=2)=C1 WRICPQCEBQENKD-UHFFFAOYSA-N 0.000 description 1
- HURHNNJEPMPUQH-UHFFFAOYSA-N 3-(3-cycloheptyloxy-4-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 HURHNNJEPMPUQH-UHFFFAOYSA-N 0.000 description 1
- KGCPXJGLQALIHW-UHFFFAOYSA-N 3-(3-cycloheptyloxy-4-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 KGCPXJGLQALIHW-UHFFFAOYSA-N 0.000 description 1
- MRDOPURDRNGDRM-UHFFFAOYSA-N 3-(3-cycloheptyloxy-4-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 MRDOPURDRNGDRM-UHFFFAOYSA-N 0.000 description 1
- FDOWUXWELQUALQ-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 FDOWUXWELQUALQ-UHFFFAOYSA-N 0.000 description 1
- SPJVNXNXVDQDIW-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-en-4-ol Chemical compound COC1=CC=C(C=2C(C3(COCC3)ON=2)O)C=C1OC1CCCC1 SPJVNXNXVDQDIW-UHFFFAOYSA-N 0.000 description 1
- YDEQBWORAZGMPA-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-en-6-ol Chemical compound COC1=CC=C(C=2CC3(C(OCC3)O)ON=2)C=C1OC1CCCC1 YDEQBWORAZGMPA-UHFFFAOYSA-N 0.000 description 1
- BCRPZCNSKWTDBC-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-en-8-ol Chemical compound COC1=CC=C(C=2CC3(CC(O)OC3)ON=2)C=C1OC1CCCC1 BCRPZCNSKWTDBC-UHFFFAOYSA-N 0.000 description 1
- DJTMCPFFAKISNL-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-en-8-one Chemical compound COC1=CC=C(C=2CC3(CC(=O)OC3)ON=2)C=C1OC1CCCC1 DJTMCPFFAKISNL-UHFFFAOYSA-N 0.000 description 1
- HWKAQOUCHZVNOH-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1,8-dioxa-2-azaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CCOCC3)C=C1OC1CCCC1 HWKAQOUCHZVNOH-UHFFFAOYSA-N 0.000 description 1
- CTBWMWUHUHTSRD-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-en-6-one Chemical compound COC1=CC=C(C=2CC3(C(NCC3)=O)ON=2)C=C1OC1CCCC1 CTBWMWUHUHTSRD-UHFFFAOYSA-N 0.000 description 1
- IUKFHAVWSAFXNA-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CNCCC3)C=C1OC1CCCC1 IUKFHAVWSAFXNA-UHFFFAOYSA-N 0.000 description 1
- FCUYXKWVFSAMAJ-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2CC3(CCCC3)ON=2)C=C1OC1CCCC1 FCUYXKWVFSAMAJ-UHFFFAOYSA-N 0.000 description 1
- DXKVMSIONQYWOY-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(O)CC3)C=C1OC1CCCC1 DXKVMSIONQYWOY-UHFFFAOYSA-N 0.000 description 1
- KPWLPNIMBMCZFS-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-one Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(=O)CC3)C=C1OC1CCCC1 KPWLPNIMBMCZFS-UHFFFAOYSA-N 0.000 description 1
- OHPKIBBSXCEWQX-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylic acid Chemical compound COC1=CC=C(C=2C(C3(CCCCC3)ON=2)C(O)=O)C=C1OC1CCCC1 OHPKIBBSXCEWQX-UHFFFAOYSA-N 0.000 description 1
- PYEVQQKUZKMUCJ-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3a,4,5,6,7,7a-hexahydro-1,2-benzoxazole Chemical compound COC1=CC=C(C=2C3CCCCC3ON=2)C=C1OC1CCCC1 PYEVQQKUZKMUCJ-UHFFFAOYSA-N 0.000 description 1
- LLUPEFVNSOGXCI-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3a,4,6,6a-tetrahydrofuro[3,4-d][1,2]oxazole Chemical compound COC1=CC=C(C=2C3COCC3ON=2)C=C1OC1CCCC1 LLUPEFVNSOGXCI-UHFFFAOYSA-N 0.000 description 1
- LTBATLZDUBAXEE-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-4,5,6,6a-tetrahydro-3ah-pyrrolo[3,4-d][1,2]oxazole Chemical compound COC1=CC=C(C=2C3CNCC3ON=2)C=C1OC1CCCC1 LTBATLZDUBAXEE-UHFFFAOYSA-N 0.000 description 1
- KYNIZDVFDAJRHA-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-5-methylsulfonyl-3a,4,6,6a-tetrahydropyrrolo[3,4-d][1,2]oxazole Chemical compound COC1=CC=C(C=2C3CN(CC3ON=2)S(C)(=O)=O)C=C1OC1CCCC1 KYNIZDVFDAJRHA-UHFFFAOYSA-N 0.000 description 1
- POUCRJUUEPVTEV-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-7-propan-2-yl-1-oxa-2,7-diazaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2CC3(CN(CC3)C(C)C)ON=2)C=C1OC1CCCC1 POUCRJUUEPVTEV-UHFFFAOYSA-N 0.000 description 1
- GIOMRKWLAYPRNT-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-(2-morpholin-4-ylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CCN2CCOCC2)CC3)C=C1OC1CCCC1 GIOMRKWLAYPRNT-UHFFFAOYSA-N 0.000 description 1
- ZUDMATROYLCAJG-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-(2-piperidin-1-ylethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CCN2CCCCC2)CC3)C=C1OC1CCCC1 ZUDMATROYLCAJG-UHFFFAOYSA-N 0.000 description 1
- HJMZEASVNPPMKK-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-(cyclopropylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CC2CC2)CC3)C=C1OC1CCCC1 HJMZEASVNPPMKK-UHFFFAOYSA-N 0.000 description 1
- BGBQFOWTYJMGAJ-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-ethenyl-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(O)(CC3)C=C)C=C1OC1CCCC1 BGBQFOWTYJMGAJ-UHFFFAOYSA-N 0.000 description 1
- QRGKFVAZEPGIGS-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-ethyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical compound C1CN(CC)CCC11ON=C(C=2C=C(OC3CCCC3)C(OC)=CC=2)C1 QRGKFVAZEPGIGS-UHFFFAOYSA-N 0.000 description 1
- BIACLODTZMNROX-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-methyl-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(C)(O)CC3)C=C1OC1CCCC1 BIACLODTZMNROX-UHFFFAOYSA-N 0.000 description 1
- ADGYMXILRKLHGL-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-8-methylsulfonyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CC3)S(C)(=O)=O)C=C1OC1CCCC1 ADGYMXILRKLHGL-UHFFFAOYSA-N 0.000 description 1
- MYSICBZTQNLMEA-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-9-methylsulfonyl-1-oxa-2,9-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CN(CCC3)S(C)(=O)=O)C=C1OC1CCCC1 MYSICBZTQNLMEA-UHFFFAOYSA-N 0.000 description 1
- RYTPICUWWDXGJO-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-n,n-dimethyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-sulfonamide Chemical compound COC1=CC=C(C=2CC3(CN(CC3)S(=O)(=O)N(C)C)ON=2)C=C1OC1CCCC1 RYTPICUWWDXGJO-UHFFFAOYSA-N 0.000 description 1
- OZPQZCXAWYBZBL-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-n-(4-fluorophenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide Chemical compound COC1=CC=C(C=2CC3(CN(CC3)C(=O)NC=3C=CC(F)=CC=3)ON=2)C=C1OC1CCCC1 OZPQZCXAWYBZBL-UHFFFAOYSA-N 0.000 description 1
- TWKAQEQNEVCRDB-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 TWKAQEQNEVCRDB-UHFFFAOYSA-N 0.000 description 1
- PQPIDIAQSPIHOH-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 PQPIDIAQSPIHOH-UHFFFAOYSA-N 0.000 description 1
- SMQDJZFRDRIIDQ-UHFFFAOYSA-N 3-(3-ethoxy-4-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCC)=CC(C=2CC3(COCC3)ON=2)=C1 SMQDJZFRDRIIDQ-UHFFFAOYSA-N 0.000 description 1
- OYCXKBRUOUTZAC-UHFFFAOYSA-N 3-(3-ethoxy-4-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC)C(OCCC)=CC=C1C(C1)=NOC11COCC1 OYCXKBRUOUTZAC-UHFFFAOYSA-N 0.000 description 1
- KUCKXJQGAZHODI-UHFFFAOYSA-N 3-(3-propan-2-yloxy-4-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCCC)=CC=C1C(C1)=NOC11COCC1 KUCKXJQGAZHODI-UHFFFAOYSA-N 0.000 description 1
- NTKQPMAZIBAFIA-UHFFFAOYSA-N 3-(4-butoxy-3-cycloheptyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 NTKQPMAZIBAFIA-UHFFFAOYSA-N 0.000 description 1
- UOQVNBUESSOEMJ-UHFFFAOYSA-N 3-(4-butoxy-3-cyclopentyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 UOQVNBUESSOEMJ-UHFFFAOYSA-N 0.000 description 1
- ZIRWVXPTGUOLKE-UHFFFAOYSA-N 3-(4-butoxy-3-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC)C(OCCCC)=CC=C1C(C1)=NOC11COCC1 ZIRWVXPTGUOLKE-UHFFFAOYSA-N 0.000 description 1
- HWXFGPQCXMTJJU-UHFFFAOYSA-N 3-(4-butoxy-3-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCCCC)=CC=C1C(C1)=NOC11COCC1 HWXFGPQCXMTJJU-UHFFFAOYSA-N 0.000 description 1
- BBDODWITNMBCQK-UHFFFAOYSA-N 3-(4-butoxy-3-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCCC)C(OCCCC)=CC=C1C(C1)=NOC11COCC1 BBDODWITNMBCQK-UHFFFAOYSA-N 0.000 description 1
- DTQUSIKUSPIGPI-UHFFFAOYSA-N 3-(4-cycloheptyloxy-3-cyclopentyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCCCC1 DTQUSIKUSPIGPI-UHFFFAOYSA-N 0.000 description 1
- YNUHVTZOPYVCJN-UHFFFAOYSA-N 3-(4-cycloheptyloxy-3-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCCCC1 YNUHVTZOPYVCJN-UHFFFAOYSA-N 0.000 description 1
- ALVPPHMNCPCJPC-UHFFFAOYSA-N 3-(4-cyclohexyloxy-3-cyclopentyloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCCC1 ALVPPHMNCPCJPC-UHFFFAOYSA-N 0.000 description 1
- XXCFKOCJKSOVEA-UHFFFAOYSA-N 3-(4-cyclopentyloxy-3-ethoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 XXCFKOCJKSOVEA-UHFFFAOYSA-N 0.000 description 1
- LYVZLUYBIHDERU-UHFFFAOYSA-N 3-(4-cyclopentyloxy-3-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 LYVZLUYBIHDERU-UHFFFAOYSA-N 0.000 description 1
- BFNNCZQGGLNRRR-UHFFFAOYSA-N 3-(4-cyclopentyloxy-3-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 BFNNCZQGGLNRRR-UHFFFAOYSA-N 0.000 description 1
- VNFOEYTYXBIHHP-UHFFFAOYSA-N 3-(4-ethoxy-3-propan-2-yloxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCC)=CC=C1C(C1)=NOC11COCC1 VNFOEYTYXBIHHP-UHFFFAOYSA-N 0.000 description 1
- KLBVEICVEPAILU-UHFFFAOYSA-N 3-(4-ethoxy-3-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC)C(OCCC)=CC(C=2CC3(COCC3)ON=2)=C1 KLBVEICVEPAILU-UHFFFAOYSA-N 0.000 description 1
- GJKSBPRVPBZCJC-UHFFFAOYSA-N 3-(4-propan-2-yloxy-3-propoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCCC)=CC(C=2CC3(COCC3)ON=2)=C1 GJKSBPRVPBZCJC-UHFFFAOYSA-N 0.000 description 1
- VMVRBFQGXXOFHL-UHFFFAOYSA-N 3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]propan-1-ol Chemical compound C1=C(OC(F)F)C(OCCCO)=CC(C=2CC3(COCC3)ON=2)=C1 VMVRBFQGXXOFHL-UHFFFAOYSA-N 0.000 description 1
- FXKUFWSHKNUIMZ-UHFFFAOYSA-N 3-[3,4-bis(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C=1C=C(C=2CC3(COCC3)ON=2)C=C(OCCN2CCOCC2)C=1OCCN1CCOCC1 FXKUFWSHKNUIMZ-UHFFFAOYSA-N 0.000 description 1
- DNTFZVFWXOTOMX-UHFFFAOYSA-N 3-[3,4-bis(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CC1 DNTFZVFWXOTOMX-UHFFFAOYSA-N 0.000 description 1
- MYUPCVLWUUABEB-UHFFFAOYSA-N 3-[3,4-di(propan-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OC(C)C)=CC=C1C(C1)=NOC11COCC1 MYUPCVLWUUABEB-UHFFFAOYSA-N 0.000 description 1
- COXSONPHLJNWNX-UHFFFAOYSA-N 3-[3-(2,3-dihydro-1h-inden-2-yloxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OCC(F)(F)F)=CC=C1C(C1)=NOC21CCOC2 COXSONPHLJNWNX-UHFFFAOYSA-N 0.000 description 1
- BCUQFBODSVHVIB-UHFFFAOYSA-N 3-[3-(2,3-dihydro-1h-inden-2-yloxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OCC)=CC=C1C(C1)=NOC21CCOC2 BCUQFBODSVHVIB-UHFFFAOYSA-N 0.000 description 1
- PESVKWPWWKYDCH-UHFFFAOYSA-N 3-[3-(2,3-dihydro-1h-inden-2-yloxy)-4-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OC(C)C)=CC=C1C(C1)=NOC21CCOC2 PESVKWPWWKYDCH-UHFFFAOYSA-N 0.000 description 1
- OLIPYYMOEKKCER-UHFFFAOYSA-N 3-[3-(2,3-dihydro-1h-inden-2-yloxy)-4-propoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OCCC)=CC=C1C(C1)=NOC21CCOC2 OLIPYYMOEKKCER-UHFFFAOYSA-N 0.000 description 1
- NDNTUOFHHHTYJE-UHFFFAOYSA-N 3-[3-(2-chloroethoxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCCCl)C(OC)=CC=C1C(C1)=NOC11COCC1 NDNTUOFHHHTYJE-UHFFFAOYSA-N 0.000 description 1
- HYLJALWRPKABLW-UHFFFAOYSA-N 3-[3-(2-methylpropoxy)-4-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCC(C)C)=CC(C=2CC3(COCC3)ON=2)=C1 HYLJALWRPKABLW-UHFFFAOYSA-N 0.000 description 1
- AZPQWVHWQAHHAS-UHFFFAOYSA-N 3-[3-(2-methylpropoxy)-4-propoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(C)C)C(OCCC)=CC=C1C(C1)=NOC11COCC1 AZPQWVHWQAHHAS-UHFFFAOYSA-N 0.000 description 1
- MJAYCNQRTRHMHZ-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 MJAYCNQRTRHMHZ-UHFFFAOYSA-N 0.000 description 1
- JMBLGALLFZAJLH-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 JMBLGALLFZAJLH-UHFFFAOYSA-N 0.000 description 1
- MPVMWHHNSDSDBF-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 MPVMWHHNSDSDBF-UHFFFAOYSA-N 0.000 description 1
- AKJREIJOXINJHE-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 AKJREIJOXINJHE-UHFFFAOYSA-N 0.000 description 1
- ISZFWUGCYLVLRM-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-cyclopentyloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCCC1COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 ISZFWUGCYLVLRM-UHFFFAOYSA-N 0.000 description 1
- MXXMKIHTALJTAL-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 MXXMKIHTALJTAL-UHFFFAOYSA-N 0.000 description 1
- GVRRUTVBIRBNHX-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 GVRRUTVBIRBNHX-UHFFFAOYSA-N 0.000 description 1
- YRAPVJDFOCBLRK-UHFFFAOYSA-N 3-[3-(cyclohexylmethoxy)-4-propoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 YRAPVJDFOCBLRK-UHFFFAOYSA-N 0.000 description 1
- YDZAHLCRNIVRAT-UHFFFAOYSA-N 3-[3-(cyclopentylmethoxy)-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCC1 YDZAHLCRNIVRAT-UHFFFAOYSA-N 0.000 description 1
- SXJWHNWLHZVCJI-UHFFFAOYSA-N 3-[3-(cyclopropylmethoxy)-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CC1 SXJWHNWLHZVCJI-UHFFFAOYSA-N 0.000 description 1
- IHAPOYOHKDKUGW-UHFFFAOYSA-N 3-[3-(cyclopropylmethoxy)-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C=1C=C(C=2CC3(COCC3)ON=2)C=C(OCC2CC2)C=1OCCN1CCOCC1 IHAPOYOHKDKUGW-UHFFFAOYSA-N 0.000 description 1
- USZKCCUWEDONCW-UHFFFAOYSA-N 3-[3-(cyclopropylmethoxy)-4-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CC1 USZKCCUWEDONCW-UHFFFAOYSA-N 0.000 description 1
- MUNDJCNMPKSEKZ-UHFFFAOYSA-N 3-[3-(cyclopropylmethoxy)-4-propoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CC1 MUNDJCNMPKSEKZ-UHFFFAOYSA-N 0.000 description 1
- CCVKXTUGWSORTJ-UHFFFAOYSA-N 3-[3-(difluoromethoxy)-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(F)F)C(OC)=CC=C1C(C1)=NOC11COCC1 CCVKXTUGWSORTJ-UHFFFAOYSA-N 0.000 description 1
- XCAHLEMBBNVZGX-UHFFFAOYSA-N 3-[3-[(2,6-dichloropyridin-4-yl)methoxy]-4-methoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1=CC(Cl)=NC(Cl)=C1 XCAHLEMBBNVZGX-UHFFFAOYSA-N 0.000 description 1
- ASEVYHAUDQBLKT-XGLRFROISA-N 3-[3-[(3s)-1-benzylpyrrolidin-3-yl]oxy-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C([C@@H](C1)OC2=CC(=CC=C2OC(F)F)C=2CC3(COCC3)ON=2)CN1CC1=CC=CC=C1 ASEVYHAUDQBLKT-XGLRFROISA-N 0.000 description 1
- LYKKKBORLKCYAT-UHFFFAOYSA-N 3-[3-butoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(F)(F)F)C(OCCCC)=CC(C=2CC3(COCC3)ON=2)=C1 LYKKKBORLKCYAT-UHFFFAOYSA-N 0.000 description 1
- GIONFEODVXOMNX-UHFFFAOYSA-N 3-[3-butoxy-4-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(C)C)C(OCCCC)=CC(C=2CC3(COCC3)ON=2)=C1 GIONFEODVXOMNX-UHFFFAOYSA-N 0.000 description 1
- JFWLFTBDMZISGG-UHFFFAOYSA-N 3-[3-butoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCCN1CCOCC1 JFWLFTBDMZISGG-UHFFFAOYSA-N 0.000 description 1
- JNXRCJKLOXAIEX-UHFFFAOYSA-N 3-[3-butoxy-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CC1 JNXRCJKLOXAIEX-UHFFFAOYSA-N 0.000 description 1
- BEZDONJGOMTQCX-UHFFFAOYSA-N 3-[3-cycloheptyloxy-4-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 BEZDONJGOMTQCX-UHFFFAOYSA-N 0.000 description 1
- BXNLCROZEBAOEM-UHFFFAOYSA-N 3-[3-cycloheptyloxy-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCCC1 BXNLCROZEBAOEM-UHFFFAOYSA-N 0.000 description 1
- BQMMOALJHYMYEJ-UHFFFAOYSA-N 3-[3-cyclohexyloxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCC1 BQMMOALJHYMYEJ-UHFFFAOYSA-N 0.000 description 1
- KWLYPJFNMTUYLT-UHFFFAOYSA-N 3-[3-cyclohexyloxy-4-(difluoromethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCCC1 KWLYPJFNMTUYLT-UHFFFAOYSA-N 0.000 description 1
- PCZCTKMVCGAKPV-UHFFFAOYSA-N 3-[3-cyclopentyloxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 PCZCTKMVCGAKPV-UHFFFAOYSA-N 0.000 description 1
- KXVPJNQUGPAAPB-UHFFFAOYSA-N 3-[3-cyclopentyloxy-4-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 KXVPJNQUGPAAPB-UHFFFAOYSA-N 0.000 description 1
- SGGVGDCUWTWMHU-UHFFFAOYSA-N 3-[3-cyclopentyloxy-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C=1C=C(C=2CC3(COCC3)ON=2)C=C(OC2CCCC2)C=1OCCN1CCOCC1 SGGVGDCUWTWMHU-UHFFFAOYSA-N 0.000 description 1
- QJPCNLDJVSWHBS-UHFFFAOYSA-N 3-[3-cyclopentyloxy-4-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 QJPCNLDJVSWHBS-UHFFFAOYSA-N 0.000 description 1
- IDRVYYBAWQRRNN-UHFFFAOYSA-N 3-[3-ethoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(F)(F)F)C(OCC)=CC(C=2CC3(COCC3)ON=2)=C1 IDRVYYBAWQRRNN-UHFFFAOYSA-N 0.000 description 1
- WFNGYIHPRFAGBV-UHFFFAOYSA-N 3-[3-ethoxy-4-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(C)C)C(OCC)=CC(C=2CC3(COCC3)ON=2)=C1 WFNGYIHPRFAGBV-UHFFFAOYSA-N 0.000 description 1
- NIRSPKVHULAAOC-UHFFFAOYSA-N 3-[3-methoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(F)(F)F)C(OC)=CC(C=2CC3(COCC3)ON=2)=C1 NIRSPKVHULAAOC-UHFFFAOYSA-N 0.000 description 1
- LZEWPQLZHUORCC-UHFFFAOYSA-N 3-[3-methoxy-4-(2-morpholin-4-ylethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCCN1CCOCC1 LZEWPQLZHUORCC-UHFFFAOYSA-N 0.000 description 1
- DDFZRKDFRSYTHO-UHFFFAOYSA-N 3-[3-phenylmethoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1=CC=CC=C1 DDFZRKDFRSYTHO-UHFFFAOYSA-N 0.000 description 1
- DUMXCRYVFUZHEO-UHFFFAOYSA-N 3-[3-propan-2-yloxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(F)(F)F)C(OC(C)C)=CC(C=2CC3(COCC3)ON=2)=C1 DUMXCRYVFUZHEO-UHFFFAOYSA-N 0.000 description 1
- MTPJMZWSBDKCLJ-UHFFFAOYSA-N 3-[3-propoxy-4-(2,2,2-trifluoroethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(F)(F)F)C(OCCC)=CC(C=2CC3(COCC3)ON=2)=C1 MTPJMZWSBDKCLJ-UHFFFAOYSA-N 0.000 description 1
- YWKLKWPNFWFWPB-UHFFFAOYSA-N 3-[4-(2-methylpropoxy)-3-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(C)C)C(OCC(C)C)=CC=C1C(C1)=NOC11COCC1 YWKLKWPNFWFWPB-UHFFFAOYSA-N 0.000 description 1
- ZRXBMVZAOPVIHP-UHFFFAOYSA-N 3-[4-(2-morpholin-4-ylethoxy)-3-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCCN1CCOCC1 ZRXBMVZAOPVIHP-UHFFFAOYSA-N 0.000 description 1
- DPYHUBSNZAVBGR-UHFFFAOYSA-N 3-[4-(2-morpholin-4-ylethoxy)-3-propoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCCN1CCOCC1 DPYHUBSNZAVBGR-UHFFFAOYSA-N 0.000 description 1
- GVDSAEZJYSKYPH-UHFFFAOYSA-N 3-[4-(cyclohexylmethoxy)-3-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CCCCC1 GVDSAEZJYSKYPH-UHFFFAOYSA-N 0.000 description 1
- ONCZWDHJARFFRP-UHFFFAOYSA-N 3-[4-(cyclohexylmethoxy)-3-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CCCCC1 ONCZWDHJARFFRP-UHFFFAOYSA-N 0.000 description 1
- UNCIGAZHUBVEQV-UHFFFAOYSA-N 3-[4-(cyclohexylmethoxy)-3-cyclopentyloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCCC1COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCCC1 UNCIGAZHUBVEQV-UHFFFAOYSA-N 0.000 description 1
- GJTXHEDRGPYHDH-UHFFFAOYSA-N 3-[4-(cyclohexylmethoxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CCCCC1 GJTXHEDRGPYHDH-UHFFFAOYSA-N 0.000 description 1
- KPHYPVPXQUXNPS-UHFFFAOYSA-N 3-[4-(cyclohexylmethoxy)-3-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CCCCC1 KPHYPVPXQUXNPS-UHFFFAOYSA-N 0.000 description 1
- JJDVFAJNTJWCGX-UHFFFAOYSA-N 3-[4-(cyclohexylmethoxy)-3-propoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CCCCC1 JJDVFAJNTJWCGX-UHFFFAOYSA-N 0.000 description 1
- WARNOZKQPMWJLB-UHFFFAOYSA-N 3-[4-(cyclopropylmethoxy)-3-(2,3-dihydro-1h-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC(C(=C1)OC2CC3=CC=CC=C3C2)=CC=C1C(C1)=NOC21CCOC2 WARNOZKQPMWJLB-UHFFFAOYSA-N 0.000 description 1
- KZLCTGTVHPPCRL-UHFFFAOYSA-N 3-[4-(cyclopropylmethoxy)-3-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CC1 KZLCTGTVHPPCRL-UHFFFAOYSA-N 0.000 description 1
- VYRDMXVRMQFAEC-UHFFFAOYSA-N 3-[4-(cyclopropylmethoxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCOC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CC1 VYRDMXVRMQFAEC-UHFFFAOYSA-N 0.000 description 1
- YRJXPQDTLOQWDY-UHFFFAOYSA-N 3-[4-(cyclopropylmethoxy)-3-propan-2-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OCC1CC1 YRJXPQDTLOQWDY-UHFFFAOYSA-N 0.000 description 1
- RUMVFKRWVRAANZ-UHFFFAOYSA-N 3-[4-(difluoromethoxy)-3-(1-ethylsulfonylpiperidin-3-yl)oxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1N(S(=O)(=O)CC)CCCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F RUMVFKRWVRAANZ-UHFFFAOYSA-N 0.000 description 1
- HQCWJGOUJLYKBD-UHFFFAOYSA-N 3-[4-(difluoromethoxy)-3-(2,3-dihydro-1h-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OC(F)F)=CC=C1C(C1)=NOC21CCOC2 HQCWJGOUJLYKBD-UHFFFAOYSA-N 0.000 description 1
- QPZRNXHSDRRMPF-WHUIICBVSA-N 3-[4-(difluoromethoxy)-3-[(3s)-pyrrolidin-3-yl]oxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1O[C@H]1CCNC1 QPZRNXHSDRRMPF-WHUIICBVSA-N 0.000 description 1
- CRDYACLYLMIMPS-UHFFFAOYSA-N 3-[4-(difluoromethoxy)-3-[1-(trifluoromethylsulfonyl)piperidin-4-yl]oxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCN(S(=O)(=O)C(F)(F)F)CC1 CRDYACLYLMIMPS-UHFFFAOYSA-N 0.000 description 1
- KKFCQSQFZILURW-YJJYDOSJSA-N 3-[4-(difluoromethoxy)-3-[[(2r)-pyrrolidin-2-yl]methoxy]phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC[C@H]1CCCN1 KKFCQSQFZILURW-YJJYDOSJSA-N 0.000 description 1
- KKFCQSQFZILURW-FVRDMJKUSA-N 3-[4-(difluoromethoxy)-3-[[(2s)-pyrrolidin-2-yl]methoxy]phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC[C@@H]1CCCN1 KKFCQSQFZILURW-FVRDMJKUSA-N 0.000 description 1
- YEPYTYURFDMLIE-UHFFFAOYSA-N 3-[4-(difluoromethoxy)-3-ethoxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC(F)F)C(OCC)=CC(C=2CC3(COCC3)ON=2)=C1 YEPYTYURFDMLIE-UHFFFAOYSA-N 0.000 description 1
- AGJRBBRYMPPSAI-UHFFFAOYSA-N 3-[4-(difluoromethoxy)-3-piperidin-4-yloxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CCNCC1 AGJRBBRYMPPSAI-UHFFFAOYSA-N 0.000 description 1
- QZHJQWRBZMOANO-UHFFFAOYSA-N 3-[4-butoxy-3-(2,3-dihydro-1h-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OC2CC3=CC=CC=C3C2)C(OCCCC)=CC=C1C(C1)=NOC21CCOC2 QZHJQWRBZMOANO-UHFFFAOYSA-N 0.000 description 1
- RQRZEXRHCUXROD-UHFFFAOYSA-N 3-[4-butoxy-3-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(C)C)C(OCCCC)=CC=C1C(C1)=NOC11COCC1 RQRZEXRHCUXROD-UHFFFAOYSA-N 0.000 description 1
- LYBVVNFPMBILKZ-UHFFFAOYSA-N 3-[4-butoxy-3-(cyclohexylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CCCCC1 LYBVVNFPMBILKZ-UHFFFAOYSA-N 0.000 description 1
- IJSSFURAHHMQOL-UHFFFAOYSA-N 3-[4-butoxy-3-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CCCCOC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1CC1 IJSSFURAHHMQOL-UHFFFAOYSA-N 0.000 description 1
- DEJBUHAOGYHWHV-UHFFFAOYSA-N 3-[4-cyclopentyloxy-3-(2,3-dihydro-1h-inden-2-yloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CCCC1OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC1CC2=CC=CC=C2C1 DEJBUHAOGYHWHV-UHFFFAOYSA-N 0.000 description 1
- CATALFUHJVUOOP-UHFFFAOYSA-N 3-[4-cyclopentyloxy-3-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound CC(C)COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 CATALFUHJVUOOP-UHFFFAOYSA-N 0.000 description 1
- KMWMLSIKBULXET-UHFFFAOYSA-N 3-[4-cyclopentyloxy-3-(cyclopropylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1CC1COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC1CCCC1 KMWMLSIKBULXET-UHFFFAOYSA-N 0.000 description 1
- FXLSDQCVRGFOEM-UHFFFAOYSA-N 3-[4-ethoxy-3-(2-methylpropoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound C1=C(OCC(C)C)C(OCC)=CC=C1C(C1)=NOC11COCC1 FXLSDQCVRGFOEM-UHFFFAOYSA-N 0.000 description 1
- IPICYQVAZDOFDK-UHFFFAOYSA-N 3-[4-methoxy-3-(3-phenylmethoxycyclopentyl)oxyphenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(C1)CCC1OCC1=CC=CC=C1 IPICYQVAZDOFDK-UHFFFAOYSA-N 0.000 description 1
- YACAXGAPGKYISB-UHFFFAOYSA-N 3-[4-methoxy-3-(pyridin-3-ylmethoxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1=CC=CN=C1 YACAXGAPGKYISB-UHFFFAOYSA-N 0.000 description 1
- OLEKHRMCCAQXSW-UHFFFAOYSA-N 3-[[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl]benzonitrile Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1=CC=CC(C#N)=C1 OLEKHRMCCAQXSW-UHFFFAOYSA-N 0.000 description 1
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 description 1
- LXFMMUDXRIMBHN-UHFFFAOYSA-N 4,4'-dichlorobenzilic acid Chemical compound C=1C=C(Cl)C=CC=1C(O)(C(=O)O)C1=CC=C(Cl)C=C1 LXFMMUDXRIMBHN-UHFFFAOYSA-N 0.000 description 1
- PFGDJQKZNFTLNM-UHFFFAOYSA-N 4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-phenylmethoxyphenol Chemical compound OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC1=CC=CC=C1 PFGDJQKZNFTLNM-UHFFFAOYSA-N 0.000 description 1
- SOCYKBZDOXWRIL-UHFFFAOYSA-N 4-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)benzene-1,2-diol Chemical compound C1=C(O)C(O)=CC=C1C(C1)=NOC11COCC1 SOCYKBZDOXWRIL-UHFFFAOYSA-N 0.000 description 1
- XYDSZTPYQGAPJO-UHFFFAOYSA-N 4-[[6-(2-methylphenyl)-8-(oxan-4-yl)-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]piperazine-1-carboxylic acid Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NN1CCN(C(O)=O)CC1 XYDSZTPYQGAPJO-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- XHAGBGFNRNIASY-UHFFFAOYSA-N 4-bromo-3-(3-cyclopentyloxy-4-methoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene Chemical compound COC1=CC=C(C=2C(C3(COCC3)ON=2)Br)C=C1OC1CCCC1 XHAGBGFNRNIASY-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- JXAIAPGBZQETQF-UHFFFAOYSA-N 5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenol Chemical compound C1=C(OCC(F)(F)F)C(O)=CC(C=2CC3(COCC3)ON=2)=C1 JXAIAPGBZQETQF-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- YEAWGQJFQXNOHH-UHFFFAOYSA-N 5-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pentanamide Chemical compound C1=C(OC(F)F)C(OCCCCC(=O)N)=CC(C=2CC3(COCC3)ON=2)=C1 YEAWGQJFQXNOHH-UHFFFAOYSA-N 0.000 description 1
- IUTNKHKTEXDLJQ-UHFFFAOYSA-N 5-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pentanoic acid Chemical compound C1=C(OC(F)F)C(OCCCCC(=O)O)=CC(C=2CC3(COCC3)ON=2)=C1 IUTNKHKTEXDLJQ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- HBYMNTJTPHPMPS-UHFFFAOYSA-N 6-(2-methylphenyl)-2-[(4-methylpiperazin-1-yl)amino]-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound C1CN(C)CCN1NC1=NC=C(C=C(C=2C(=CC=CC=2)C)C(=O)N2C3CCOCC3)C2=N1 HBYMNTJTPHPMPS-UHFFFAOYSA-N 0.000 description 1
- AQYWZFMGAFXLMI-UHFFFAOYSA-N 6-(2-methylphenyl)-8-(oxan-4-yl)-2-(piperidin-1-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NN1CCCCC1 AQYWZFMGAFXLMI-UHFFFAOYSA-N 0.000 description 1
- XYQYVKYXBQBUOB-UHFFFAOYSA-N 6-(2-methylphenyl)-8-(oxan-4-yl)-2-(piperidin-4-ylamino)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NC1CCNCC1 XYQYVKYXBQBUOB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ITBSVYDQYCMHMW-UHFFFAOYSA-N 7-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-en-6-one Chemical compound COC1=CC=C(C=2CC3(C(N(N)CC3)=O)ON=2)C=C1OC1CCCC1 ITBSVYDQYCMHMW-UHFFFAOYSA-N 0.000 description 1
- SVJYUTVNJHMTRG-UHFFFAOYSA-N 8-benzyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CC=2C=CC=CC=2)CC3)C=C1OC1CCCC1 SVJYUTVNJHMTRG-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ZMYGOSBRLPSJNB-SOMXGXJRSA-N Amelometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O ZMYGOSBRLPSJNB-SOMXGXJRSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- CVJSSAUPCRRJMA-LREBCSMRSA-N C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C)(=O)OC1=CC=CC=C1 Chemical compound C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C)(=O)OC1=CC=CC=C1 CVJSSAUPCRRJMA-LREBCSMRSA-N 0.000 description 1
- MQMLUHHBJPCXJE-UHFFFAOYSA-N CNC1CCCC1.CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NN1CCN(C(O)=O)CC1 Chemical compound CNC1CCCC1.CC1=CC=CC=C1C(C(N(C1CCOCC1)C1=N2)=O)=CC1=CN=C2NN1CCN(C(O)=O)CC1 MQMLUHHBJPCXJE-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Dexbudesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940126083 M3 antagonist Drugs 0.000 description 1
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 1
- 101150030891 MRAS gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- GZHFODJQISUKAY-UHFFFAOYSA-N Methantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 GZHFODJQISUKAY-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- XLISACWEDCQPRB-UHFFFAOYSA-N N-(cyclohexylmethyl)-3,3,3-triphenyl-N-piperidin-1-ylpropanamide Chemical class C1(=CC=CC=C1)C(CC(=O)N(CC1CCCCC1)N1CCCCC1)(C1=CC=CC=C1)C1=CC=CC=C1 XLISACWEDCQPRB-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- NZPJYPTZUPYUJT-LJQANCHMSA-N N-[7-cyclopropyl-2-methoxy-4-[[(1R)-1-phenylethyl]amino]quinazolin-6-yl]-4-morpholin-4-ylbut-2-enamide Chemical compound C1([C@@H](C)NC=2N=C(N=C3C=C(C(NC(=O)C=CCN4CCOCC4)=CC3=2)C2CC2)OC)=CC=CC=C1 NZPJYPTZUPYUJT-LJQANCHMSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MVLBCBPGBUAVJQ-CENSZEJFSA-N [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-17-(chloromethylsulfanylcarbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O MVLBCBPGBUAVJQ-CENSZEJFSA-N 0.000 description 1
- BTQQATHCFLVWGI-UHFFFAOYSA-N [2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl] benzoate Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(=O)C1=CC=CC=C1 BTQQATHCFLVWGI-UHFFFAOYSA-N 0.000 description 1
- VBTLDSIJVHUTGN-UHFFFAOYSA-N [2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl] cyclohexanecarboxylate Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(=O)C1CCCCC1 VBTLDSIJVHUTGN-UHFFFAOYSA-N 0.000 description 1
- AYPNEMBMJAZDIC-UHFFFAOYSA-N [2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl] cyclopropanecarboxylate Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(=O)C1CC1 AYPNEMBMJAZDIC-UHFFFAOYSA-N 0.000 description 1
- RUTQCFLEKYLYNZ-UHFFFAOYSA-N [2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenyl] morpholine-4-carboxylate Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(=O)N1CCOCC1 RUTQCFLEKYLYNZ-UHFFFAOYSA-N 0.000 description 1
- UYVYDRXVNVNQEA-BJTOFBPUSA-N [2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 4-(acetamidomethyl)cyclohexane-1-carboxylate Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)COC(=O)C1CCC(CNC(C)=O)CC1 UYVYDRXVNVNQEA-BJTOFBPUSA-N 0.000 description 1
- JTKZNDWRAHGHLN-UHFFFAOYSA-N [3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-en-7-yl]-(oxolan-3-yl)methanone Chemical compound COC1=CC=C(C=2CC3(CN(CC3)C(=O)C3COCC3)ON=2)C=C1OC1CCCC1 JTKZNDWRAHGHLN-UHFFFAOYSA-N 0.000 description 1
- CYQJVOVSGZMWKO-UHFFFAOYSA-N [3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-en-7-yl]-cyclopropylmethanone Chemical compound COC1=CC=C(C=2CC3(CN(CC3)C(=O)C3CC3)ON=2)C=C1OC1CCCC1 CYQJVOVSGZMWKO-UHFFFAOYSA-N 0.000 description 1
- LFJMITGOWVBPLH-IBGZPJMESA-N [3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[(2s)-pyrrolidin-2-yl]methanone Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CC3)C(=O)[C@H]2NCCC2)C=C1OC1CCCC1 LFJMITGOWVBPLH-IBGZPJMESA-N 0.000 description 1
- QIFDQJQXMOBDES-UHFFFAOYSA-N [3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(C1)CCCN1C(=O)C1=CC=C(F)C=C1 QIFDQJQXMOBDES-UHFFFAOYSA-N 0.000 description 1
- RWQGWCZKKARSPD-UHFFFAOYSA-N [4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(CC1)CCN1C(=O)C1=CC=C(F)C=C1 RWQGWCZKKARSPD-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229950008046 amelometasone Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229950011341 cloticasone Drugs 0.000 description 1
- 229940097480 cogentin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- QTBCATBNRIYMPB-UHFFFAOYSA-N cyclohexyl-hydroxy-phenyl-(3-piperidin-1-ylpropyl)silane Chemical compound C1CCCCC1[Si](C=1C=CC=CC=1)(O)CCCN1CCCCC1 QTBCATBNRIYMPB-UHFFFAOYSA-N 0.000 description 1
- DHCBDZBAOMEZQE-UHFFFAOYSA-N cyclopentyl-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-en-9-yl]methanone Chemical compound COC1=CC=C(C=2CC3(ON=2)CN(CCC3)C(=O)C2CCCC2)C=C1OC1CCCC1 DHCBDZBAOMEZQE-UHFFFAOYSA-N 0.000 description 1
- PJSADAFDKGDXMW-UHFFFAOYSA-N cyclopentyl-[3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]methanone Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(C1)CCCN1C(=O)C1CCCC1 PJSADAFDKGDXMW-UHFFFAOYSA-N 0.000 description 1
- UWJVDRITORMIFS-UHFFFAOYSA-N cyclopentyl-[4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]methanone Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(CC1)CCN1C(=O)C1CCCC1 UWJVDRITORMIFS-UHFFFAOYSA-N 0.000 description 1
- HKZMHOCVDAIYKG-UHFFFAOYSA-N cyclopropyl-[4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidin-1-yl]methanone Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OC(CC1)CCN1C(=O)C1CC1 HKZMHOCVDAIYKG-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229950007161 deprodone Drugs 0.000 description 1
- 229950003658 dexbudesonide Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- POCBQLKKAIVCOG-UHFFFAOYSA-N ethyl 2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenoxy]acetate Chemical compound C1=C(OCC(F)(F)F)C(OCC(=O)OCC)=CC(C=2CC3(COCC3)ON=2)=C1 POCBQLKKAIVCOG-UHFFFAOYSA-N 0.000 description 1
- ODRFRBOBDWUQES-UHFFFAOYSA-N ethyl 3-[[4-[[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]amino]-4-oxobut-2-enyl]-(2-ethoxy-2-oxoethyl)amino]propanoate Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CCC(=O)OCC)CC(=O)OCC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ODRFRBOBDWUQES-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 229950008940 halopredone Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 229960001470 methantheline Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- ALMHSXDYCFOZQD-UHFFFAOYSA-N n-(3-methylphenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(C)=C1 ALMHSXDYCFOZQD-UHFFFAOYSA-N 0.000 description 1
- QWGFJPDRQJMAPJ-SFHVURJKSA-N n-[2-[2-[4-[(2s)-5-oxooxolane-2-carbonyl]piperazin-1-yl]ethoxy]quinazolin-6-yl]prop-2-enamide Chemical compound N1=CC2=CC(NC(=O)C=C)=CC=C2N=C1OCCN(CC1)CCN1C(=O)[C@@H]1CCC(=O)O1 QWGFJPDRQJMAPJ-SFHVURJKSA-N 0.000 description 1
- XDQUMHOZJSDRKK-UHFFFAOYSA-N n-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl]-2-fluorobenzamide Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(CC3)NC(=O)C=2C(=CC=CC=2)F)C=C1OC1CCCC1 XDQUMHOZJSDRKK-UHFFFAOYSA-N 0.000 description 1
- KOJAFJRQKDOUDD-UHFFFAOYSA-N n-[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl]benzamide Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(CC3)NC(=O)C=2C=CC=CC=2)C=C1OC1CCCC1 KOJAFJRQKDOUDD-UHFFFAOYSA-N 0.000 description 1
- MPIZUARKKMOKKZ-MRXNPFEDSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[4-[(2r)-2-methyl-6-oxomorpholin-4-yl]butoxy]quinazolin-6-yl]prop-2-enamide Chemical compound C1C(=O)O[C@H](C)CN1CCCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C MPIZUARKKMOKKZ-MRXNPFEDSA-N 0.000 description 1
- MPIZUARKKMOKKZ-INIZCTEOSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[4-[(2s)-2-methyl-6-oxomorpholin-4-yl]butoxy]quinazolin-6-yl]prop-2-enamide Chemical compound C1C(=O)O[C@@H](C)CN1CCCCOC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C MPIZUARKKMOKKZ-INIZCTEOSA-N 0.000 description 1
- PPJGSQYDBPIBAZ-UHFFFAOYSA-N n-benzyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenoxy]acetamide Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC(=O)NCC1=CC=CC=C1 PPJGSQYDBPIBAZ-UHFFFAOYSA-N 0.000 description 1
- NVWFDBYERXNPJX-UHFFFAOYSA-N n-benzyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide Chemical compound COC1=CC=C(C=2CC3(CN(CC3)C(=O)NCC=3C=CC=CC=3)ON=2)C=C1OC1CCCC1 NVWFDBYERXNPJX-UHFFFAOYSA-N 0.000 description 1
- CZXXYYCZSUYGOZ-UHFFFAOYSA-N n-benzyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide Chemical compound COC1=CC=C(C=2CC3(ON=2)CCN(CC3)C(=O)NCC=2C=CC=CC=2)C=C1OC1CCCC1 CZXXYYCZSUYGOZ-UHFFFAOYSA-N 0.000 description 1
- AZXWLEUXFVJXBE-UHFFFAOYSA-N n-butyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-carboxamide Chemical compound C1N(C(=O)NCCCC)CCC21ON=C(C=1C=C(OC3CCCC3)C(OC)=CC=1)C2 AZXWLEUXFVJXBE-UHFFFAOYSA-N 0.000 description 1
- BHORIYAGWDWHKC-UHFFFAOYSA-N n-butyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-8-carboxamide Chemical compound C1CN(C(=O)NCCCC)CCC11ON=C(C=2C=C(OC3CCCC3)C(OC)=CC=2)C1 BHORIYAGWDWHKC-UHFFFAOYSA-N 0.000 description 1
- JIUBDOYSGTZBGJ-UHFFFAOYSA-N n-butyl-3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-9-carboxamide Chemical compound C1N(C(=O)NCCCC)CCCC11ON=C(C=2C=C(OC3CCCC3)C(OC)=CC=2)C1 JIUBDOYSGTZBGJ-UHFFFAOYSA-N 0.000 description 1
- SQCSYQVNDCMRCE-UHFFFAOYSA-N n-cyclopentyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenoxy]acetamide Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC(=O)NC1CCCC1 SQCSYQVNDCMRCE-UHFFFAOYSA-N 0.000 description 1
- CBEJRQJYGPDALT-UHFFFAOYSA-N n-cyclopropyl-2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetamide Chemical compound FC(F)OC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC(=O)NC1CC1 CBEJRQJYGPDALT-UHFFFAOYSA-N 0.000 description 1
- MBVRPQATEATQRS-UHFFFAOYSA-N n-cyclopropyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-(2,2,2-trifluoroethoxy)phenoxy]acetamide Chemical compound FC(F)(F)COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC(=O)NC1CC1 MBVRPQATEATQRS-UHFFFAOYSA-N 0.000 description 1
- HMIPIXIYNRAEHR-UHFFFAOYSA-N n-cyclopropyl-2-[5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetamide Chemical compound COC1=CC=C(C=2CC3(COCC3)ON=2)C=C1OCC(=O)NC1CC1 HMIPIXIYNRAEHR-UHFFFAOYSA-N 0.000 description 1
- KKTBUCVHSCATGB-UHFFFAOYSA-N n-methylcyclopentanamine Chemical compound CNC1CCCC1 KKTBUCVHSCATGB-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical class CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 229960002794 prednicarbate Drugs 0.000 description 1
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 229950000366 roxindole Drugs 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950004351 telenzepine Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- SRRQBHBQSJPBSF-GZWBLTSWSA-N tert-butyl (2s)-2-[[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1COC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F SRRQBHBQSJPBSF-GZWBLTSWSA-N 0.000 description 1
- OMVVJADQPFQYKT-JGHKVMFLSA-N tert-butyl (3r)-3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@H]1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F OMVVJADQPFQYKT-JGHKVMFLSA-N 0.000 description 1
- OMVVJADQPFQYKT-UEDXYCIISA-N tert-butyl (3s)-3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC[C@@H]1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F OMVVJADQPFQYKT-UEDXYCIISA-N 0.000 description 1
- VMQJUYTXCQHUJI-UHFFFAOYSA-N tert-butyl 2-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]acetate Chemical compound C1=C(OC(F)F)C(OCC(=O)OC(C)(C)C)=CC(C=2CC3(COCC3)ON=2)=C1 VMQJUYTXCQHUJI-UHFFFAOYSA-N 0.000 description 1
- UUXULYLAARCZOB-UHFFFAOYSA-N tert-butyl 3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2,9-diazaspiro[4.5]dec-2-ene-9-carboxylate Chemical compound COC1=CC=C(C=2CC3(ON=2)CN(CCC3)C(=O)OC(C)(C)C)C=C1OC1CCCC1 UUXULYLAARCZOB-UHFFFAOYSA-N 0.000 description 1
- HVAAVUCZFDDQIT-UHFFFAOYSA-N tert-butyl 3-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F HVAAVUCZFDDQIT-UHFFFAOYSA-N 0.000 description 1
- NQQYDQPLXULKSP-UHFFFAOYSA-N tert-butyl 4-[2-(difluoromethoxy)-5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(C=2CC3(COCC3)ON=2)=CC=C1OC(F)F NQQYDQPLXULKSP-UHFFFAOYSA-N 0.000 description 1
- QYSQEGLLWDLAMA-UHFFFAOYSA-N tert-butyl n-[[3-(3-cyclopentyloxy-4-methoxyphenyl)-1-oxa-2-azaspiro[4.5]dec-2-en-8-yl]carbamoyl]carbamate Chemical compound COC1=CC=C(C=2CC3(ON=2)CCC(CC3)NC(=O)NC(=O)OC(C)(C)C)C=C1OC1CCCC1 QYSQEGLLWDLAMA-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- HNDGEYCCZGRMTN-UHFFFAOYSA-N thieno[3,2-f:4,5-f]bis[1]benzothiophene Chemical compound S1C2=CC=3SC=CC=3C=C2C2=C1C=C(SC=C1)C1=C2 HNDGEYCCZGRMTN-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229960004631 tixocortol Drugs 0.000 description 1
- YWDBSCORAARPPF-VWUMJDOOSA-N tixocortol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CS)[C@@H]4[C@@H]3CCC2=C1 YWDBSCORAARPPF-VWUMJDOOSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000005062 tracheal ring Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960002249 ulobetasol Drugs 0.000 description 1
- LEHFPXVYPMWYQD-XHIJKXOTSA-N ulobetasol Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O LEHFPXVYPMWYQD-XHIJKXOTSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2794DE2005 | 2005-10-19 | ||
| IN2794/DEL/2005 | 2005-10-19 | ||
| PCT/IB2006/002930 WO2007045979A1 (en) | 2005-10-19 | 2006-10-19 | Pharmaceutical compositions of muscarinic receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2626612A1 true CA2626612A1 (en) | 2007-04-26 |
Family
ID=37527068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002626612A Abandoned CA2626612A1 (en) | 2005-10-19 | 2006-10-19 | Pharmaceutical compositions of muscarinic receptor antagonists |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090221664A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1948164A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009512676A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006305619A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0617674A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2626612A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008119323A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007045979A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825147B2 (en) | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| US20080009535A1 (en) * | 2004-08-30 | 2008-01-10 | Sarala Balachandran | Inhibitors of phosphodiesterase type-IV |
| EP2059505A2 (en) * | 2006-09-04 | 2009-05-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| EA200900472A1 (ru) * | 2006-09-22 | 2009-10-30 | Ранбакси Лабораторис Лимитед | Ингибиторы фосфодиэстеразы iv типа |
| US20100152269A1 (en) * | 2006-12-21 | 2010-06-17 | Ranbaxy Laboratories Limited | Modified-release formulations of azabicyclo derivatives |
| EP2111861A1 (en) * | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| TW201517906A (zh) * | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US598621A (en) | 1898-02-08 | Refrigerating apparatus | ||
| US605344A (en) | 1898-06-07 | sabin | ||
| US630517A (en) | 1899-04-05 | 1899-08-08 | Edward L Perry | Composition for printers' inking-rollers. |
| NL124473C (cg-RX-API-DMAC7.html) | 1960-07-26 | |||
| GB1047518A (en) | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
| NL128816C (cg-RX-API-DMAC7.html) | 1965-04-22 | |||
| GB1158492A (en) | 1966-02-09 | 1969-07-16 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
| GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US3937838A (en) | 1966-10-19 | 1976-02-10 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds and their preparation |
| US3639434A (en) | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
| US3780177A (en) | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
| CH540244A (de) | 1967-11-17 | 1973-08-15 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Halogenpregnadiene |
| GB1253831A (en) | 1968-01-19 | 1971-11-17 | Glaxo Lab Ltd | 9alpha,21-DIHALOPREGNANE COMPOUNDS |
| US3700681A (en) | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
| US3947478A (en) | 1972-01-12 | 1976-03-30 | Akzona Incorporated | Alkylated 3,20-diketo-Δ4 -steroids of the pregnane series |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (cg-RX-API-DMAC7.html) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3992534A (en) * | 1972-05-19 | 1976-11-16 | Ab Bofors | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods |
| SE378110B (cg-RX-API-DMAC7.html) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| FR2231374B1 (cg-RX-API-DMAC7.html) | 1973-05-30 | 1976-10-22 | Jouveinal Sa | |
| US4098804A (en) | 1973-05-30 | 1978-07-04 | Jouveinal S.A. | Esters of 21-thiol prednisone and prednisolone |
| US4011258A (en) | 1973-06-21 | 1977-03-08 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds |
| ZA744259B (en) | 1973-08-17 | 1975-06-25 | American Cyanamid Co | Topical steroid |
| US3980778A (en) | 1973-10-25 | 1976-09-14 | The Upjohn Company | Anti-inflammatory steroid |
| NL7502252A (nl) | 1974-02-27 | 1975-08-29 | Pierrel Spa | Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden. |
| DE2655570A1 (de) | 1975-12-12 | 1977-06-16 | Ciba Geigy Ag | Neue polyhalogensteroide und verfahren zu ihrer herstellung |
| US4076708A (en) | 1976-12-22 | 1978-02-28 | Schering Corporation | Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby |
| US4124707A (en) | 1976-12-22 | 1978-11-07 | Schering Corporation | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor |
| US4081541A (en) | 1976-12-28 | 1978-03-28 | Rorer Italiana S.P.A. | Steroid derivatives |
| DE2735110A1 (de) | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
| JPS6040439B2 (ja) | 1978-03-29 | 1985-09-11 | 大正製薬株式会社 | ヒドロコルチゾン誘導体 |
| BE887518A (fr) | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | Cartothioates d'androstanes |
| DE3163871D1 (en) | 1980-07-09 | 1984-07-05 | Draco Ab | 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates |
| US4298604B1 (en) | 1980-10-06 | 1998-12-22 | Schering Corp | Clotrimazole-betamethasone dipropionate combination |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| DE3133081A1 (de) | 1981-08-18 | 1983-03-10 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung |
| US4472392A (en) | 1983-01-21 | 1984-09-18 | The Upjohn Company | Sulfonate containing ester prodrugs of corticosteroids |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| CA1240708A (en) | 1983-11-15 | 1988-08-16 | Johannes K. Minderhoud | Process for the preparation of hydrocarbons |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| CA1326662C (en) | 1988-03-09 | 1994-02-01 | Yutaka Mizushima | 11.beta.,17.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(e,e)-3,7,11-trimethyl-2,6,10-dodecatrienoate] |
| US5278156A (en) | 1988-03-09 | 1994-01-11 | Kuraray Co., Ltd. | 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate] |
| US5001160A (en) | 1988-04-28 | 1991-03-19 | Marion Laboratories, Inc. | 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders |
| GB8906166D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| US5281601A (en) | 1989-12-12 | 1994-01-25 | Pfizer Inc. | Muscarinic receptor antagonists |
| GB8928042D0 (en) | 1989-12-12 | 1990-02-14 | Pfizer Ltd | Muscarinic receptor antagonists |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| HU213401B (en) | 1990-09-10 | 1997-06-30 | Schering Corp | Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| GB9202443D0 (en) | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
| FI100051B (fi) | 1992-02-18 | 1997-09-15 | Favorit Oy | Kompostori |
| JP3429338B2 (ja) | 1992-07-27 | 2003-07-22 | 杏林製薬株式会社 | 新規なアリールグリシンアミド誘導体及びその製造法 |
| JPH06135958A (ja) | 1992-10-28 | 1994-05-17 | Tanabe Seiyaku Co Ltd | ベンゾシクロヘプテン誘導体及びその製法 |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| DZ1966A1 (fr) | 1995-02-06 | 2002-10-15 | Astra Ab | Combinaison pharmaceutique nouvelle. |
| US5750540A (en) | 1995-04-28 | 1998-05-12 | Banyu Pharmaceutical Co., Ltd. | 1,4-di-substituted piperidine derivatives |
| ES2172583T3 (es) | 1995-06-06 | 2002-10-01 | Pfizer | 5,6-dihidro-9h-pirazol(3,4-c)-1,2,4-triazol(4,3-alfa)piridinas triciclicas. |
| CA2179574A1 (en) | 1995-06-26 | 1996-12-27 | Tomomi Okada | Substituted piperidine derivative and medicine comprising the same |
| ATE205490T1 (de) | 1995-10-13 | 2001-09-15 | Banyu Pharma Co Ltd | Substituierte heteroaromatische derivate |
| AU2793197A (en) | 1996-05-31 | 1998-01-05 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituted piperidine derivatives |
| US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| PE92198A1 (es) | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| PL189641B1 (pl) | 1996-11-11 | 2005-09-30 | Altana Pharma Ag | Benzonaftyrydyny, środki farmaceutyczne je zawierające oraz zastosowanie benzonaftyrydyn |
| KR20000057548A (ko) | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| PL198983B1 (pl) | 1998-04-28 | 2008-08-29 | Elbion Ag | Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania |
| ITMI981670A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4 |
| GB9824160D0 (en) | 1998-11-04 | 1998-12-30 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| DE60021282T2 (de) | 1999-12-07 | 2006-05-18 | Theravance, Inc., South San Francisco | Carbamat-derivate als muscarin-rezeptor antonisten |
| IL152701A0 (en) | 2000-05-25 | 2003-06-24 | Hoffmann La Roche | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| US20020052312A1 (en) * | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| US20030199494A1 (en) | 2000-06-14 | 2003-10-23 | Paul Evans | 1,2,3,5-tetrahydrobenzo'c!azepin-4-one derivatives having muscarinic antagonist activity |
| KR100751981B1 (ko) | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
| DE10050994A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE60121813T2 (de) | 2000-12-28 | 2007-09-20 | Almirall Ag | Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten |
| AU2002345266B2 (en) * | 2002-07-08 | 2009-07-02 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| JP2006522787A (ja) * | 2003-04-11 | 2006-10-05 | ランバクシー ラボラトリーズ リミテッド | ムスカリン様受容体アンタゴニストとしてのアザビシクロ誘導体 |
| CA2522666A1 (en) * | 2003-04-18 | 2004-10-28 | Pharmacia & Upjohn Company Llc | Combination therapies for chronic obstructive pulmonary disease (copd) |
| US7825147B2 (en) | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| EP1713471B1 (en) * | 2004-02-06 | 2012-01-18 | MEDA Pharma GmbH & Co. KG | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| WO2005092341A1 (en) * | 2004-03-22 | 2005-10-06 | Ranbaxy Laboratories Limited | Combination therapy for lower urinary tract symptoms |
| WO2006003587A2 (en) * | 2004-07-01 | 2006-01-12 | Ranbaxy Laboratories Limited | Solid oral dosage forms of azabicyclo derivatives |
| EP1828126A1 (en) * | 2004-12-15 | 2007-09-05 | Ranbaxy Laboratories Limited | Acid addition salts of muscarinic receptor antagonists |
| WO2006117754A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists |
| BRPI0617673C1 (pt) * | 2005-10-19 | 2012-05-22 | Ranbaxy Lab Ltd | composições de inibidores de fosfodiesterase do tipo iv |
-
2006
- 2006-10-19 AU AU2006305619A patent/AU2006305619A1/en not_active Abandoned
- 2006-10-19 RU RU2008119323/15A patent/RU2008119323A/ru not_active Application Discontinuation
- 2006-10-19 WO PCT/IB2006/002930 patent/WO2007045979A1/en not_active Ceased
- 2006-10-19 US US12/090,805 patent/US20090221664A1/en not_active Abandoned
- 2006-10-19 EP EP06809068A patent/EP1948164A1/en not_active Withdrawn
- 2006-10-19 BR BRPI0617674-7A patent/BRPI0617674A2/pt not_active IP Right Cessation
- 2006-10-19 JP JP2008536146A patent/JP2009512676A/ja not_active Withdrawn
- 2006-10-19 CA CA002626612A patent/CA2626612A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009512676A (ja) | 2009-03-26 |
| RU2008119323A (ru) | 2009-11-27 |
| AU2006305619A1 (en) | 2007-04-26 |
| US20090221664A1 (en) | 2009-09-03 |
| EP1948164A1 (en) | 2008-07-30 |
| BRPI0617674A2 (pt) | 2011-08-02 |
| WO2007045979A1 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2339624C2 (ru) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ | |
| US8093268B2 (en) | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) | |
| US8710047B2 (en) | 5-HT3 receptor modulators, methods of making, and use thereof | |
| JP2005523288A (ja) | 疾病治療用の縮合した二環式−n−架橋−複素環式芳香族カルボキサミド | |
| TW200932236A (en) | Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase | |
| JP5675943B2 (ja) | ロイコトリエンa4加水分解酵素の調節因子としてのチアゾロピリジン−2−イルオキシ−フェニル及びチアゾロピラジン−2−イルオキシ−フェニルアミン | |
| JP2021528447A (ja) | ムスカリンm1および/またはm4受容体のアゴニストとしてのオキサジアゾール | |
| US20090326032A1 (en) | Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers | |
| CA2626612A1 (en) | Pharmaceutical compositions of muscarinic receptor antagonists | |
| JP2010504323A (ja) | Iv型ホスホジエステラーゼの阻害物質 | |
| CN1326456A (zh) | 8-氮杂二环[3,.2.1]辛-2-烯及-辛烷衍生物 | |
| US20090054382A1 (en) | Compositions of phosphodiesterase type iv inhibitors | |
| TW202115017A (zh) | 小分子menin抑制劑 | |
| US20100004215A1 (en) | Compositions of phosphodiesterase type iv inhibitors | |
| JP2009263234A (ja) | ホスホジエステラーゼタイプiv阻害剤の組成物 | |
| EP2189451A1 (en) | Benzamide derivatives, their preparation and uses in medicine thereof | |
| CN1886130A (zh) | 2-硫杂-二苯并[e,h]薁在制备治疗和预防中枢神经系统疾病和障碍的药物制剂中的应用 | |
| EP2111861A1 (en) | Compositions of phosphodiesterase type IV inhibitors | |
| US20250213564A1 (en) | Compositions and methods for the treatment of alzheimer's disease and other neurogenerative disease | |
| EP4389223A1 (en) | Synthesis, pharmacology and use of new water-soluble and selective fms-like tyrosine kinase 3 (flt3) inhibitors | |
| CA2629547A1 (en) | Compositions of phosphodiesterase type iv inhibitors | |
| HK1138179A (en) | Compositions of phosphodiesterase type iv inhibitors | |
| TW200300673A (en) | Azabicyclic-phenyl-fused-heterocyclic compounds for treatement of disease | |
| HK1057536B (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation | |
| HK1057536A1 (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |